Filing Flows › Sarepta Therapeutics (SRPT) › Stock forecast & fair value
Sarepta Therapeutics (SRPT) stock forecast and fair value
Sarepta Therapeutics (SRPT) trades at $17.82. 22 analysts' median price target is $20.00 (+12%), from $5.00 to $38.00. Across 13 valuation methods the middle fair value is $21.68 (+22%).
Fair value by method
| Method | Low | Point | High | vs price |
|---|---|---|---|---|
| EV/Sales vs peers | $43.85 | $73.04 | $146.29 | +310% |
| EV/Sales vs peers, weighted | $60.68 | $101.36 | $159.56 | +469% |
| EV/Sales vs peers, matched | $19.08 | $21.05 | $40.05 | +18% |
| Residual income | $6.04 | $6.26 | $6.50 | -65% |
| Analysts' price targets | $5.00 | $21.68 | $38.00 | +22% |
| Shareholder yield (dividends + buybacks) | $2.53 | $2.83 | $3.20 | -84% |
| Tangible book (asset value) | $11.54 | $14.42 | $14.42 | -19% |
| Survival-weighted value | $40.97 | $67.55 | $134.25 | +279% |
| Stage-weighted value (decline / turnaround) | $30.16 | $48.13 | $90.33 | +170% |
| Combined forecast (3 months) | $14.59 | $18.53 | $22.96 | +4% |
Sarepta Therapeutics' latest quarter
Sarepta Therapeutics, Q3 2026: revenue $381M (-4% year over year), operating margin -2.4%, net loss $28.5M, operating cash flow $60.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for SRPT stock?
The median of 22 analysts' 12-month targets is $20.00, +12% from $17.82; the range is $5.00 to $38.00. The average rating is hold.
What is Sarepta Therapeutics' fair value?
The fair-value methods on Filing Flows (DCF, Monte Carlo, peer multiples and others) put it between $2.83 and $101.36, with a middle value of $21.68 against a price of $17.82. Each method's assumptions are on the page.
Does Sarepta Therapeutics usually beat earnings estimates?
It beat the consensus EPS estimate in 60% of the quarters on record.
Is SRPT stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.